ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.

Background: Emerging mutations in the ESR1 gene that encodes for the estrogen receptor (ER) are associated with resistance to endocrine therapy. ESR1 mutations rarely exist in primary tumors (~ 1%) but are relatively common (10-50%) in metastatic, endocrine therapy-resistant cancers and are associat...

Descripción completa

Detalles Bibliográficos

Publicado en:	Breast Cancer Research Vol. 22; no. 1; pp. 1 - 12
Autores principales:	Zundelevich, Adi, Dadiani, Maya, Kahana-Edwin, Smadar, Itay, Amit, Sella, Tal, Gadot, Moran, Cesarkas, Karen, Farage-Barhom, Sarit, Saar, Efrat Glick, Eyal, Eran, Kol, Nitzan, Pavlovski, Anya, Balint-Lahat, Nora, Dick-Necula, Daniela, Barshack, Iris, Kaufman, Bella, Gal-Yam, Einav Nili
Formato:	research Journal Article
Publicado:	BioMed Central 2/3/2020
Acceso en línea:	Ver este registro en EBSCOhost